Research field (1)：
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (2)：
2022 - 2026 Treatment response and prognosis prediction of immune checkpoint inhibitors by FDG-PET/CT: A Japanese multicenter prospective study
2019 - 2022 Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.
Papers (54)：
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. Journal of Clinical Investigation. 2024. 134. 7
Daisuke Hazama, Kenji Nakahama, Hiroaki Kodama, Akito Miyazaki, Koichi Azuma, Yosuke Kawashima, Yuki Sato, Kentaro Ito, Yoshimasa Shiraishi, Keita Miura, et al. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma. JTO clinical and research reports. 2024. 5. 1. 100613-100613
Yasushi Goto, Hirotsugu Kenmotsu, Motohiro Tamiya, Shuji Murakami, Takayasu Kurata, Noriko Yanagitani, Hirokazu Taniguchi, Shoichi Kuyama, Junichi Shimizu, Toshihide Yokoyama, et al. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan. JTO Clinical and Research Reports. 2023. 4. 5. 100508-100508
Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo. Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma. Case Reports in Medicine. 2023. 2023. 1-4
米阪仁雄, 稲垣千昌, 稲垣千昌, 高濱隆幸, 高濱隆幸, 白石直樹, 磯本晃佑, 金村宙昌, 鈴木慎一郎, 谷崎潤子, et al. Providing Anti-Lung Cancer Drug Therapy Based on Genetic Information by Comprehensive Genomic Profiling. 日本癌学会学術総会抄録集(Web). 2023. 82nd
2003 - 2009 Kagawa University Faculty of Medicine School of Medicine
Professional career (1)：
M.D., Ph. D. (Kindai University)
Work history (9)：
2022/04 - 現在 Kindai University Kindai University Hospotal
2021/04 - 2022/03 Kindai University Department of medical oncology
2020/04 - 2021/03 Kindai University Nara Hospital Kindai University
2019/04 - 2020/03 Kindai University Nara Hospital Kindai University
2015/04 - 2019/03 Kindai University Faculty of Medicine
2013/04 - 2015/03 Kindai University Kindai University Hospotal
2012/04 - 2013/03 Kagawa University
2011/04 - 2012/03 Kagawa prefectural central hospital Respiratory medicine
2009/04 - 2011/03 Kagawa prefectural central hospital
Show all
Committee career (7)：
2024/02 - 現在 The Japanese society of medical oncology Specialist committee
2023/12 - 現在 International Association for the Study of Lung Cancer The Global Multidisciplinary Practice Standards Committee (GMPSC)
2023/05 - 現在 West Japan Oncology Group Education and Public Relations Committee
2022/04 - 現在 The Japanese Respiratory Society Adult Pneumonia Practice Guideline 2022 Preparation Committee Member of the Systematic Review Committee
2019/07 - 現在 Japanese Lung Cancer Society Guidelines Review Committee Subcommittee on Guidelines for Patients
2022/03 - 2024/02 Japan Society of Medical Oncology Member of the Supervisory Medical Examination Section
2017/07 - 2023/03 Ministry of Health, Labour and Welfare Commissioned Project for Training of Personnel Engaged in Genomic Medicine for Cancer Genomic Medicine Worker Training Committee
Show all
Awards (2)：
2020/09 - Nara medical association Nara medical association Young Researcher's Award
2017/05 - West Japan Oncology Group Ariyoshi/Fukuoka Prize
Association Membership(s) (8)：
THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER
, THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY
, THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES
, THE JAPAN LUNG CANCER SOCIETY
, THE JAPANESE RESPIRATORY SOCIETY
, THE JAPANESE CANCER ASSOCIATION
, 日本臨床腫瘍学会
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
